Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.68 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5623594 | 0.93 | ELANE (0.69) | ELANECYP3A4CYP2C9CYP2C8CYP2C19 | |
| SCHEMBL8344545 | 0.92 | ELANE (0.78) | ELANECYP3A4CYP2C9CYP2C8CYP2C19 | |
| SCHEMBL5205452 | 0.90 | ELANE (0.75) | ELANECYP3A4CYP2C9CYP2C8CYP2C19 | |
| SCHEMBL5205336 | 0.90 | ELANE (0.67) | ELANECYP3A4CYP2C9 | |
| SCHEMBL5202886 | 0.88 | ELANE (1.00) | ELANECYP3A4CYP2C9CYP2C8CYP2C19 | |
| SCHEMBL10090359 | 0.87 | ELANE (0.71) | ELANECYP3A4CYP2C9CYP2C8CYP2C19 | |
| SCHEMBL10090346 | 0.86 | ELANE (0.68) | ELANECYP3A4CYP2C9ADRB1HTR1A | |
| SCHEMBL333051 | 0.86 | ELANE (0.83) | ELANECYP3A4CYP2C9CYP2C8CYP2C19 | |
| SCHEMBL8285582 | 0.86 | ELANE (0.68) | ELANECYP3A4CYP2C9CYP2C8CYP2C19 | |
| SCHEMBL10090407 | 0.86 | ELANE (0.70) | ELANECYP3A4CYP2C9CYP2C8CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097629-B2 | Dihydropyridinone derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-17 | — | — | US | disclosed |
| US-8097629-B2 | Dihydropyridinone derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-17 | — | — | US | disclosed |
| US-8097629-B2 | Dihydropyridinone derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-17 | — | — | US | disclosed |
| EP-1720857-B1 | DIHYDROPYRIDINONE DERIVATIVES | BAYER SCHERING PHARMA AG (DE) | 2011-07-13 | — | — | EP | disclosed |
| US-20080045541-A1 | Dihydropyridinone Derivatives | BAYER-HEALTHCARE AG (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045541-A1 | Dihydropyridinone Derivatives | BAYER-HEALTHCARE AG (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045541-A1 | Dihydropyridinone Derivatives | BAYER-HEALTHCARE AG (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045541-A1 | Dihydropyridinone Derivatives | TNNI3, DHPS, TNNT2 | ELANE 260/4885CYP3A4 3343/4885CYP2C9 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.